WST Stock Overview
Designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
West Pharmaceutical Services, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$331.40 |
| 52 Week High | US$413.70 |
| 52 Week Low | US$265.00 |
| Beta | 1.01 |
| 1 Month Change | 6.33% |
| 3 Month Change | 7.55% |
| 1 Year Change | -6.63% |
| 3 Year Change | -27.93% |
| 5 Year Change | 119.75% |
| Change since IPO | 25,924.06% |
Recent News & Updates
Should You Think About Buying West Pharmaceutical Services, Inc. (NYSE:WST) Now?
Nov 15
West Pharmaceutical Services, Inc. Just Recorded A 27% EPS Beat: Here's What Analysts Are Forecasting Next
Oct 27Recent updates
Should You Think About Buying West Pharmaceutical Services, Inc. (NYSE:WST) Now?
Nov 15West Pharmaceutical Services, Inc. Just Recorded A 27% EPS Beat: Here's What Analysts Are Forecasting Next
Oct 27West Pharma's Destocking Dilemma: Why Staying On The Sidelines Makes Sense
Oct 11Getting In Cheap On West Pharmaceutical Services, Inc. (NYSE:WST) Is Unlikely
Sep 20A Look At The Intrinsic Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
Sep 02West Pharmaceutical Services, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
Jul 28West Pharmaceutical: Continued Destocking And A High Valuation Post Q2 Results (Rating Maintained)
Jul 25Is It Time To Consider Buying West Pharmaceutical Services, Inc. (NYSE:WST)?
Jul 15We Think West Pharmaceutical Services (NYSE:WST) Can Stay On Top Of Its Debt
Jun 27Estimating The Fair Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
May 21West Pharmaceutical: Pick And Shovels Of The Injectable Drug Industry
May 11West Pharmaceutical Services, Inc.'s (NYSE:WST) Business Is Yet to Catch Up With Its Share Price
Mar 30Is West Pharmaceutical Services (NYSE:WST) A Risky Investment?
Mar 12Why West Pharma Is Far From Done
Feb 28West Pharmaceutical Services, Inc.'s (NYSE:WST) Intrinsic Value Is Potentially 19% Below Its Share Price
Feb 20West Pharmaceutical Services: Still Too Expensive After The Recent Drop
Feb 20What Does West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Indicate?
Jan 10West Pharmaceutical: Great Business, Not So Great Valuation
Jan 08West Pharmaceutical Services: The Run Might Be Over
Oct 18West Pharmaceutical: Revise To Buy On Exceptional Economic Characteristics
Aug 08West Pharmaceutical: Hard To Justify The Price
May 26West Pharmaceutical Q4 2022 Earnings Preview
Feb 15West Pharmaceutical: An Earnings Decline Seen In 2023, Shares Still Appear Expensive
Dec 19West Pharmaceutical declares $0.19 dividend
Dec 13Shareholder Returns
| WST | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0.4% | -3.7% | -3.5% |
| 1Y | -6.6% | -6.6% | 22.1% |
Return vs Industry: WST matched the US Life Sciences industry which returned -6.6% over the past year.
Return vs Market: WST underperformed the US Market which returned 22.1% over the past year.
Price Volatility
| WST volatility | |
|---|---|
| WST Average Weekly Movement | 6.3% |
| Life Sciences Industry Average Movement | 9.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: WST has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: WST's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 10,600 | Eric Green | www.westpharma.com |
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components.
West Pharmaceutical Services, Inc. Fundamentals Summary
| WST fundamental statistics | |
|---|---|
| Market cap | US$23.68b |
| Earnings (TTM) | US$499.60m |
| Revenue (TTM) | US$2.88b |
48.0x
P/E Ratio8.3x
P/S RatioIs WST overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WST income statement (TTM) | |
|---|---|
| Revenue | US$2.88b |
| Cost of Revenue | US$1.87b |
| Gross Profit | US$1.00b |
| Other Expenses | US$503.40m |
| Earnings | US$499.60m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.90 |
| Gross Margin | 34.87% |
| Net Profit Margin | 17.37% |
| Debt/Equity Ratio | 7.4% |
How did WST perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield12%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 23:09 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
West Pharmaceutical Services, Inc. is covered by 28 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Lawrence Marsh | Barclays |
| Michael Ryskin | BofA Global Research |